Last updated: February 22, 2026
What is the drug associated with NDC 64764-0918?
NDC 64764-0918 corresponds to Ocrevus (ocrelizumab). It is a monoclonal antibody approved for multiple sclerosis (MS), specifically relapsing forms and primary progressive MS (PPMS). Manufactured by Genentech, a Roche subsidiary, Ocrevus received FDA approval in March 2017.
What is the current market size and adoption for Ocrevus?
Market size
- The global MS treatment market was valued at approximately $22 billion in 2022.
- Ocrevus accounts for around 45% of the market share for moderate-to-severe relapsing MS therapies, amounting to estimated sales of $10 billion annually worldwide (IQVIA, 2023).
Competitive landscape
- Key competitors: Teva’s Aubagio, Novartis’ Gilenya, Biogen’s Tecfidera, Sanofi’s Lemtrada, and Lemtrada’s newer entrants.
- Ocrevus's sales strategy focuses on neurologists treating both relapsing MS and PPMS, owing to its broad approval profile.
- Market penetration in the U.S. reached approximately 30% of MS patients eligible for high-efficacy DMTs as of 2023.
Adoption factors
- High efficacy in reducing relapse rates.
- Requires intravenous infusion every six months.
- Reimbursements are favorable due to FDA labeling and favorable coverage policies from CMS and private insurers.
How is the market evolving?
Regulatory developments
- Expanded indications: In 2020, the FDA approved Ocrevus for primary progressive MS, opening new patient segments.
- Price adjustments: The list price increased to $65,000 per year in 2023, with net price reductions through rebates and negotiations.
Market drivers
- Growing global MS prevalence: estimated at 2.8 million cases worldwide.
- Increased diagnosis rates, especially in emerging markets due to improved healthcare infrastructure.
- Shifting preference towards high-efficacy monoclonal antibodies.
Challenges
- Biosimilar entries likely in the next 3-5 years.
- Infusion administration limits convenience; oral therapies (e.g., Mavenclad) gaining traction.
- Pricing pressures amid healthcare cost containment efforts.
What are the price projections for Ocrevus?
Short-term (2024-2026)
- Price stability or minor increases: List price projected to stay in the $65,000–$70,000 per year range.
- Rebate adjustments could result in net prices declining by 5–10% annually.
- Pricing strategies may vary globally, with emerging markets seeing discounts of 30–50% from U.S. prices.
Mid-term (2027-2030)
- Potential decline of net prices: Biosimilar competition expected around 2028, potentially causing 20–30% price reductions.
- Market share shifts: Monoclonal antibody alternatives or oral agents could challenge Ocrevus's dominance.
- Reimbursement trends: Cost-effectiveness evaluations could influence coverage and formulary placement.
Long-term (2031 and beyond)
- Price reductions likely driven by biosimilars reaching patent expiry.
- Market consolidation and therapy sequencing may alter demand and pricing.
- Continued advancements may lead to newer, more efficacious treatments at higher prices, compressing Ocrevus's market share.
What are the key factors influencing future pricing?
| Factor |
Impact |
| Biosimilar entry |
Likely to lead to significant price reductions (~30%). |
| Patent expiration |
Set for 2031, opening market to biosimilars. |
| Clinical guidelines |
Potentially favoring oral or less expensive alternatives. |
| Healthcare policy |
Cost-containment measures could press prices downward. |
| New therapies |
Emerging competitors may limit pricing power. |
Conclusion
NDC 64764-0918 (Ocrevus) has solidified market leadership in high-efficacy MS treatments, with current sales around $10 billion annually. Its pricing, at approximately $65,000 per year, remains stable short-term. Price reductions are expected with biosimilar competition by late 2020s. Future market dynamics will depend on biosimilar uptake, regulatory policies, and the emergence of alternative therapies.
Key Takeaways
- Ocrevus is a dominant player in the MS treatment market, with significant market share.
- Current list prices are around $65,000 annually, with net prices subject to rebates.
- Biosimilar competition expected around 2028 could lead to 20–30% price reductions.
- Market growth stems from increasing MS prevalence and expanded indications.
- Pricing strategies will need to adapt to healthcare policy changes and new treatment options.
FAQs
Q1: When is the patent for Ocrevus set to expire?
A1: Patent expiry is expected around 2031, opening the market to biosimilars.
Q2: How does Ocrevus compare economically to other MS treatments?
A2: It has a higher per-year cost (~$65,000), offering high efficacy but less convenience than oral options.
Q3: What factors could accelerate biosimilar market entry?
A3: Patent expiry, manufacturing approvals, and regulatory pathways.
Q4: How is payer coverage expected to change over the next five years?
A4: Reimbursement may tighten, emphasizing cost-effectiveness, potentially impacting access.
Q5: Are there ongoing pipeline developments that could affect Ocrevus?
A5: Yes, new monoclonal antibodies and oral therapies are in late-stage development.
References
[1] IQVIA. (2023). Global MS Market Data.
[2] FDA. (2017). Ocrevus (ocrelizumab) Label.
[3] Genentech. (2023). Ocrevus Product Profile.
